Roche Holding AG (Roche Holding AG) Inventories, Other

: $0 Mil (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Roche Holding AG's other inventories for the quarter that ended in Dec. 2023 was $0 Mil.

Roche Holding AG's quarterly other inventories increased from Dec. 2022 ($0 Mil) to Jun. 2023 ($9,436 Mil) but then declined from Jun. 2023 ($9,436 Mil) to Dec. 2023 ($0 Mil).

Roche Holding AG Inventories, Other Historical Data

The historical data trend for Roche Holding AG's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roche Holding AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Other

Get a 7-Day Free Trial

Roche Holding AG Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Inventories, Other	Get a 7-Day Free Trial															-	8,546.69	-	9,435.81	-

Roche Holding AG Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.

Roche Holding AG (Roche Holding AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (OTCPK:RHHBY) » Definitions » Inventories, Other

Comparable Companies

Traded in Other Exchanges

RHHVF:USA RHHBF:USA ROG N:Mexico ROz:UK ROGz:UK 0QOK:UK RHO6:Germany ROG:Switzerland RO:Switzerland

Address

Grenzacherstrasse 124, Basel, CHE, 4070

Website

https://www.roche.com

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.